CCG-LTFI: A Groupwide Protocol for Collecting Follow- up Data
Children's Cancer Group clinical trials are conducted to improve understanding of the
biology and treatment of childhood cancers. Protocols are developed by expert committees and
distributed from the Group Operations Center to the member institutions. Before a protocol
can be opened to patient accrual at a CCG institution, the protocol, consent form and any
activation amendments are reviewed and approved by the local Institutional Review Board
QRB).
Protocols remain open to patient accrual until sufficient evaluable patients have been
entered to answer the study questions. During this time, the protocol and any new amendments
are reviewed annually by the IRB. When the study has been closed to patient accrual it
remains open solely for the purpose of collecting life status and occurrence of adverse
events. The IRB must continue its annual review as long as a patient treated on the protocol
is alive and follow-up data are being collected. The CCG Long Term Follow-up protocol
(CCG-LTF1) is meant to allow continued collective review of all protocols that meet the
following criteria: (a) It is closed to patient accrual, (b) all patients have completed
treatment, and (c) there are patients who are alive and being followed. The protocols that
meet these criteria will be listed as being aggregated under CCG-LTF1 such that an IRB
review of CCG-LTF1 will constitute a review of that protocol.
Observational
Time Perspective: Prospective
Facilitate reporting of adverse events for those who completed treatment; To establish a mechanism for regular annual approval; Decrease the number of active protocols; Develop a framework for future studies of long-term health related outcomes.
2 years
No
Peter Steinherz, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
99-068
NCT00588289
September 1999
December 2013
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |